initial public offerings (IPOs) trading on American exchanges

Saturday, November 28, 2015

CytomX Therapeutics (CTMX) began trading on the NASDAQ on 8 Oct 2015


343 Oyster Point Blvd., Suite 100
United States 

Key stats and ratios

Q2 (Jun '15)2014
Net profit margin-214.10%-597.01%
Operating margin-271.27%-586.27%
EBITD margin--570.85%
Return on average assets-17.43%-69.48%
Return on average equity--


CytomX Therapeutics, Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs, which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company's pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company's additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.

No comments:

Post a Comment